Stock 600812 NORTH CHINA PHARMACEUTICAL COMPANY.LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials North China Pharmaceutical Company.Ltd

Equities

600812

CNE000000D16

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
5.27 CNY -0.57% Intraday chart for North China Pharmaceutical Company.Ltd +2.53% -7.54%
Apr. 25 North China Pharmaceutical Company.Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 30 North China Pharmaceutical Company.Ltd agreed to acquire the remaining 35.85% stake in NCPC Hebei Huamin Pharmaceutical Co., Ltd. from CCB Financial Asset Investment Co., Ltd. for CNY 670 million CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 6,523 16,047 16,781 20,452 10,981 9,780
Enterprise Value (EV) 1 14,266 24,177 25,126 28,923 20,346 19,939
P/E ratio 43.5 x 105 x 172 x 1,084 x -15.9 x 1,900 x
Yield 0.75% 0.3% 0.29% 0.5% - 0.18%
Capitalization / Revenue 0.71 x 1.47 x 1.46 x 1.97 x 1.05 x 0.97 x
EV / Revenue 1.55 x 2.22 x 2.19 x 2.79 x 1.94 x 1.97 x
EV / EBITDA 14.2 x 19.6 x 20.8 x 23.7 x 15.2 x 15.7 x
EV / FCF 77.7 x -18.7 x -30.9 x -32 x 112 x 128 x
FCF Yield 1.29% -5.36% -3.24% -3.12% 0.89% 0.78%
Price to Book 1.2 x 2.89 x 2.74 x 3.36 x 2.07 x 1.84 x
Nbr of stocks (in thousands) 1,630,805 1,630,805 1,630,805 1,715,730 1,715,730 1,715,730
Reference price 2 4.000 9.840 10.29 11.92 6.400 5.700
Announcement Date 3/22/19 3/30/20 4/28/21 4/27/22 4/21/23 3/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 9,214 10,881 11,493 10,385 10,500 10,120
EBITDA 1 1,004 1,235 1,209 1,221 1,343 1,272
EBIT 1 460.4 667.4 597.9 600.1 634.8 536.4
Operating Margin 5% 6.13% 5.2% 5.78% 6.05% 5.3%
Earnings before Tax (EBT) 1 198.4 236.9 186.7 134.9 -565.1 158.5
Net income 1 150.6 153.4 97.32 18.73 -689.2 4.89
Net margin 1.64% 1.41% 0.85% 0.18% -6.56% 0.05%
EPS 2 0.0920 0.0940 0.0600 0.0110 -0.4020 0.003000
Free Cash Flow 1 183.7 -1,296 -814.2 -902.5 181.3 156.1
FCF margin 1.99% -11.91% -7.08% -8.69% 1.73% 1.54%
FCF Conversion (EBITDA) 18.29% - - - 13.5% 12.27%
FCF Conversion (Net income) 121.94% - - - - 3,191.74%
Dividend per Share 2 0.0300 0.0300 0.0300 0.0600 - 0.0100
Announcement Date 3/22/19 3/30/20 4/28/21 4/27/22 4/21/23 3/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 7,743 8,130 8,345 8,472 9,366 10,159
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 7.709 x 6.585 x 6.9 x 6.94 x 6.974 x 7.989 x
Free Cash Flow 1 184 -1,296 -814 -902 181 156
ROE (net income / shareholders' equity) 2.7% 2.66% 1.63% 0.5% -10.2% 0.79%
ROA (Net income/ Total Assets) 1.64% 2.29% 1.74% 1.54% 1.72% 1.59%
Assets 1 9,180 6,706 5,580 1,220 -40,088 307.6
Book Value Per Share 2 3.340 3.410 3.760 3.550 3.090 3.100
Cash Flow per Share 2 0.7700 0.7500 3.010 3.090 0.9800 0.5800
Capex 1 507 646 1,007 547 550 623
Capex / Sales 5.5% 5.94% 8.76% 5.27% 5.23% 6.16%
Announcement Date 3/22/19 3/30/20 4/28/21 4/27/22 4/21/23 3/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
NORTH CHINA PHARMACEUTICAL COMPANY.LTD Stock North China Pharmaceutical Company.Ltd
-7.54% 1.26B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.94% 690B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.43% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.02% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.11% 323B
ABBVIE INC. Stock AbbVie Inc.
+4.57% 287B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 235B
NOVARTIS AG Stock Novartis AG
+5.79% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.49% 195B
AMGEN INC. Stock Amgen Inc.
+4.02% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600812 Stock
  4. Financials North China Pharmaceutical Company.Ltd
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW